




A **HC176 VVPRRKAKIIRDYGK (Pol)**
 VID 413 - A*01:01 (A01) A*03:01 (A03) B*08:01 (B08) B*44:02 (B44) C*05:01 C*07:01
VVPRRKAKII/HLA-B*08:01 Not predicted, not reported, confirmed B*08:01, 'A-list' candidate
RKAKIIRDYGK/HLA-B*08:01 Not predicted, not reported, confirmed B*08:01, 'A-list' candidate
KIIRDYGK/HLA-B*08:01 Predicted A*03:01, not reported, confirmed B*08:01, 'A-list' candidate



S19 Fig. HC176 VVPRRKAKIIRDYGK (Pol) - Definition of CD8⁺ T-cell determinants. (A) The box. Peptide HC176 was recognized by volunteer 413 of the indicated HLA type. Optimal peptides and their HLA restriction are shown. (B) Cryopreserved lymphocytes from the vaccine recipient were expanded by stimulation with 'parental' peptide for 10 days to establish STCL, which was subjected to ICS using serially truncated peptides. IFN- γ (green) and TNF- α (orange) production and surface expression of CD107a (pink) served as the read-out. Arrows next to an amino acid indicate the peptide-terminal amino acid residue required for efficient peptide recognition. (C) The same SCTLs as in (B) were tested for recognition of overlapping 9-mer peptides. (D) 721.221 cells expressing HLA-B*08:01 were used to confirm binding peptides.